These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

607 related items for PubMed ID: 32088495

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J, Wang Y, Li Y, Xu L, Cao D, Song S, Damaneh MS, Wang X, Meng T, Chen YL, Shen J, Miao Z, Xiong B.
    Eur J Med Chem; 2017 Sep 08; 137():176-195. PubMed ID: 28586718
    [Abstract] [Full Text] [Related]

  • 3. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
    Lv X, Yang X, Zhan MM, Cao P, Zheng S, Peng R, Han J, Xie Z, Tu Z, Liao C.
    Eur J Med Chem; 2019 Dec 15; 184():111769. PubMed ID: 31629162
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a hydrazone moiety as potent PLK1 inhibitors.
    Li Z, Xu L, Zhu L, Zhao Y, Hu T, Yin B, Liu Y, Hou Y.
    Bioorg Med Chem Lett; 2020 Aug 15; 30(16):127329. PubMed ID: 32631534
    [Abstract] [Full Text] [Related]

  • 5. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R, Wang WL, Yang YY, Hu XT, Wang QW, Zuo WQ, Xu Y, Feng Q, Wang NY.
    Eur J Med Chem; 2022 Jan 05; 227():113922. PubMed ID: 34700270
    [Abstract] [Full Text] [Related]

  • 6. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X, Bai L, Xu Y, Wang J, Lu H.
    Biochem Biophys Res Commun; 2020 Jan 22; 521(4):833-839. PubMed ID: 31708096
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design, synthesis and biological evaluation of novel 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as potential BRD4 inhibitors.
    Bi X, Li J, Li J, Shi W, Dai Y, Li Q, Zhang W, Huang W, Qian H, Jiang C.
    Bioorg Med Chem; 2019 Jul 01; 27(13):2813-2821. PubMed ID: 31079968
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY, Luo F, Li XY, Fu XF, He JF, Tian YZ, Zhu JJ, Chu XY, Zhao HL.
    Anticancer Agents Med Chem; 2019 Jul 01; 19(6):740-749. PubMed ID: 30836927
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, and biological evaluation of novel 4,4-difluoro-1-methyl-N, 6-diphenyl-5, 6-dihydro-4H-pyrimido [4, 5-b] [1, 2, 4] triazolo [4, 3-d] [1, 4] diazepin-8-amine derivatives as potential BRD4 inhibitors.
    Li J, Zhang W, Qiu Q, Zhou D, Feng Z, Tong Z, Wei J, Huang W, Li J, Qian H, Shi W.
    Chem Biol Drug Des; 2021 May 01; 97(5):1117-1128. PubMed ID: 33638254
    [Abstract] [Full Text] [Related]

  • 11. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
    Li P, Li Y, Ma X, Li L, Zeng S, Peng Y, Liang H, Zhang G.
    Eur J Med Chem; 2024 May 05; 271():116416. PubMed ID: 38657480
    [Abstract] [Full Text] [Related]

  • 12. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
    Liu S, Yosief HO, Dai L, Huang H, Dhawan G, Zhang X, Muthengi AM, Roberts J, Buckley DL, Perry JA, Wu L, Bradner JE, Qi J, Zhang W.
    J Med Chem; 2018 Sep 13; 61(17):7785-7795. PubMed ID: 30125504
    [Abstract] [Full Text] [Related]

  • 13. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S, Bartkovitz D, Cai J, Chen Y, Chen Z, Chu XJ, Le K, Le NT, Luk KC, Mischke S, Naderi-Oboodi G, Boylan JF, Nevins T, Qing W, Chen Y, Wovkulich PM.
    Bioorg Med Chem Lett; 2012 Jan 15; 22(2):1247-50. PubMed ID: 22172702
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1.
    Sun J, Liu HY, Xu RF, Zhu HL.
    Bioorg Med Chem; 2017 Dec 15; 25(24):6581-6588. PubMed ID: 29100732
    [Abstract] [Full Text] [Related]

  • 16. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA, Brassesco MS, Ramos PMM, Scrideli CA, Tone LG.
    Anticancer Agents Med Chem; 2017 Dec 15; 17(9):1278-1291. PubMed ID: 28270075
    [Abstract] [Full Text] [Related]

  • 17. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA, Sakr H, Ayyad RRA, El-Adl K, Ali MM, Khedr F.
    Anticancer Agents Med Chem; 2018 Dec 15; 18(8):1184-1196. PubMed ID: 29651967
    [Abstract] [Full Text] [Related]

  • 18. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM.
    Cancer Lett; 2017 Apr 28; 392():71-82. PubMed ID: 28126323
    [Abstract] [Full Text] [Related]

  • 19. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
    Chapagai D, Ramamoorthy G, Varghese J, Nurmemmedov E, McInnes C, Wyatt MD.
    J Med Chem; 2021 Jul 22; 64(14):9916-9925. PubMed ID: 34210138
    [Abstract] [Full Text] [Related]

  • 20. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD, Ndiaye MA, Huang W, Liu X, Ahmad N.
    Cancer Lett; 2017 Jan 28; 385():179-187. PubMed ID: 27793694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.